首页> 美国卫生研究院文献>Journal of Nanotechnology in Engineering and Medicine >Cellular Uptake and Intracellular Cargo Release From Dextran Based Nanogel Drug Carriers
【2h】

Cellular Uptake and Intracellular Cargo Release From Dextran Based Nanogel Drug Carriers

机译:基于葡聚糖的纳米凝胶药物载体的细胞吸收和细胞内货物释放

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Nanogels (NG) hold great promise as a drug delivery platform. In this work, we examine the potential of lysozyme-dextran nanogels (LDNG) as drug carriers in vitro using two cell lines: a model target tissue, human umbilical cord vein endothelial cells (HUVEC) and a model of the mononuclear phagocyte system (phorbol 12-myristate 13-acetate (PMA)-stimulated THP-1 cells). The LDNG (∼100 nm) were prepared with rhodamine-label dextran (LRDNG) via Maillard reaction followed by heat-gelation reaction and were loaded with a fluorescent probe, 5-hexadecanoylaminofluorescein (HAF), as a mock drug. Epifluorescence microscopy confirmed rapid uptake of LRDNG by HUVEC. Although LysoTracker Green staining indicated a lysosomal fate for LRDNG, the mock drug cargo (HAF) diffused extensively inside the cell within 15 min. Flow cytometry and confocal microscopy indicated slow uptake of LRDNG in PMA-stimulated THP-1 cells, with only 41% of cells containing LRDNG after 24 h exposure. Finally, 24 h exposure to LRDNG did not affect the viability of either cell type at the dose studied (20 μg/ml). At a higher dose (200 μg/ml), LRDNG resulted in a marked loss of viability of HUVEC and THP-1, measuring 30% and 38%, respectively. Collectively, our results demonstrate the great potential of LRDNG as a drug delivery platform, combining simple production, rapid uptake and cargo release in target cells with “stealth” properties and low cytotoxicity.
机译:纳米凝胶(NG)有望作为药物输送平台。在这项工作中,我们使用两种细胞系检查了溶菌酶-葡聚糖纳米凝胶(LDNG)在体外作为药物载体的潜力:一种模型靶组织,人脐带静脉内皮细胞(HUVEC)和一种单核吞噬细胞系统(phorbol) 12-肉豆蔻酸酯13-乙酸酯(PMA)刺激的THP-1细胞)。通过美拉德反应,然后通过热凝胶化反应,用罗丹明标记的葡聚糖(LRDNG)制备LDNG(〜100 nm),并装载作为模拟药物的荧光探针5-十六烷酰氨基荧光素(HAF)。荧光显微镜证实HUVEC迅速吸收了LRDNG。尽管LysoTracker Green染色显示LRDNG的溶酶体命运,但模拟药物货物(HAF)在15分钟内在细胞内广泛扩散。流式细胞术和共聚焦显微镜检查表明,PMA刺激的THP-1细胞中LRDNG的吸收缓慢,暴露24小时后只有41%的细胞含有LRDNG。最后,在研究剂量(20μg/ ml)下,LRDNG暴露24h不会影响任何一种细胞的活力。在较高剂量(200μg/ ml)下,LRDNG导致HUVEC和THP-1的活力显着下降,分别为30%和38%。总的来说,我们的结果证明了LRDNG作为药物递送平台的巨大潜力,将简单的生产,快速的摄取和靶细胞中的货物释放与“隐身”特性和低细胞毒性相结合。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号